• Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.
• FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury
• Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently

 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.